Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 86,224Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Pomalyst /Imnovid

02 5Pomalyst/Imnovid

03 3Pomalyst/Imnovid

04 1Pomalyst/Imnovid - BMS

05 1Pomalyst/Imnovid - Celgene

PharmaCompass

01

Brand Name : Pomalyst/Imnovid

Pomalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Pomalyst/Imnovid

arrow
2024 ACI Convention
Not Confirmed

Pomalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 3,070

2019 Revenue in Millions : 2,162

Growth (%) : 42

blank

02

Brand Name : Pomalyst/Imnovid

Pomalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Pomalyst/Imnovid

arrow
2024 ACI Convention
Not Confirmed

Pomalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 3,332

2020 Revenue in Millions : 3,070

Growth (%) : 9

blank

03

Brand Name : Pomalyst/Imnovid

Pomalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Pomalyst/Imnovid

arrow
2024 ACI Convention
Not Confirmed

Pomalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 3,497

2021 Revenue in Millions : 3,332

Growth (%) : 5

blank

04

Brand Name : Pomalyst/Imnovid

Pomalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Pomalyst/Imnovid

arrow
2024 ACI Convention
Not Confirmed

Pomalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 3,441

2022 Revenue in Millions : 3,497

Growth (%) : -2

blank

05

Brand Name : Pomalyst /Imnovid

Pomalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Pomalyst /Imnovid

arrow
2024 ACI Convention
Not Confirmed

Pomalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2015 Revenue in Millions : 680

2014 Revenue in Millions : 983

Growth (%) : 45%

blank

06

Brand Name : Pomalyst/Imnovid

Pomalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Pomalyst/Imnovid

arrow
2024 ACI Convention
Not Confirmed

Pomalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 1,614

2016 Revenue in Millions : 1,311

Growth (%) : 23

blank

07

Brand Name : Pomalyst/Imnovid

Pomalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Pomalyst/Imnovid

arrow
2024 ACI Convention
Not Confirmed

Pomalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2016 Revenue in Millions : 1,311

2015 Revenue in Millions : 983

Growth (%) : 33

blank

08

Brand Name : Pomalyst/Imnovid

Pomalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Pomalyst/Imnovid

arrow
2024 ACI Convention
Not Confirmed

Pomalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 2,040

2017 Revenue in Millions : 1,614

Growth (%) : 26%

blank

09

Brand Name : Pomalyst/Imnovid - BMS

Pomalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Pomalyst/Imnovid - BMS

arrow
2024 ACI Convention
Not Confirmed

Pomalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 322

2018 Revenue in Millions : 0

Growth (%) : N/A

blank

10

Brand Name : Pomalyst/Imnovid - Celgene

Pomalidomide

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Pomalyst/Imnovid - Celgene

arrow
2024 ACI Convention
Not Confirmed

Pomalidomide

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 1,840

2018 Revenue in Millions : 2,040

Growth (%) : N/A

blank